GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Beneish M-Score

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Beneish M-Score : -3.69 (As of Apr. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Cumberland Pharmaceuticals's Beneish M-Score or its related term are showing as below:

CPIX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.69   Med: -2.66   Max: -2.44
Current: -3.69

During the past 13 years, the highest Beneish M-Score of Cumberland Pharmaceuticals was -2.44. The lowest was -3.69. And the median was -2.66.


Cumberland Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Cumberland Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals Beneish M-Score Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.67 -2.44 -3.58 -2.52 -3.69

Cumberland Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -3.22 -3.30 -3.36 -3.69

Competitive Comparison of Cumberland Pharmaceuticals's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Beneish M-Score falls into.



Cumberland Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cumberland Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7873+0.528 * 0.9248+0.404 * 1.0671+0.892 * 0.9415+0.115 * 1.0923
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1516+4.679 * -0.19595-0.327 * 1.0603
=-3.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $9.76 Mil.
Revenue was 9.353 + 10.086 + 10.889 + 9.225 = $39.55 Mil.
Gross Profit was 7.823 + 8.32 + 9.368 + 7.974 = $33.49 Mil.
Total Current Assets was $35.71 Mil.
Total Assets was $81.78 Mil.
Property, Plant and Equipment(Net PPE) was $7.04 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.77 Mil.
Selling, General, & Admin. Expense(SGA) was $29.10 Mil.
Total Current Liabilities was $27.98 Mil.
Long-Term Debt & Capital Lease Obligation was $18.08 Mil.
Net Income was -6.294 + -1.049 + 0.872 + 0.192 = $-6.28 Mil.
Non Operating Income was 0 + 0.822 + 0.982 + 1.847 = $3.65 Mil.
Cash Flow from Operations was 1.04 + 1.237 + 5.235 + -1.418 = $6.09 Mil.
Total Receivables was $13.16 Mil.
Revenue was 9.124 + 11.413 + 10.299 + 11.175 = $42.01 Mil.
Gross Profit was 6.473 + 9.189 + 8.267 + 8.963 = $32.89 Mil.
Total Current Assets was $45.87 Mil.
Total Assets was $92.93 Mil.
Property, Plant and Equipment(Net PPE) was $5.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.33 Mil.
Selling, General, & Admin. Expense(SGA) was $26.84 Mil.
Total Current Liabilities was $28.58 Mil.
Long-Term Debt & Capital Lease Obligation was $20.79 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9.758 / 39.553) / (13.164 / 42.011)
=0.246707 / 0.313347
=0.7873

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(32.892 / 42.011) / (33.485 / 39.553)
=0.782938 / 0.846586
=0.9248

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (35.714 + 7.042) / 81.776) / (1 - (45.87 + 5.502) / 92.925)
=0.477157 / 0.447167
=1.0671

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=39.553 / 42.011
=0.9415

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.328 / (5.328 + 5.502)) / (5.771 / (5.771 + 7.042))
=0.491967 / 0.450402
=1.0923

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(29.103 / 39.553) / (26.842 / 42.011)
=0.735798 / 0.638928
=1.1516

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((18.08 + 27.982) / 81.776) / ((20.786 + 28.58) / 92.925)
=0.56327 / 0.531246
=1.0603

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.279 - 3.651 - 6.094) / 81.776
=-0.19595

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cumberland Pharmaceuticals has a M-score of -3.69 suggests that the company is unlikely to be a manipulator.


Cumberland Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830